CPX-351 Plus Ivosidenib
Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 30 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Chemotherapy, Isocitrate Dehydrogenase 1 (IDH1) Inhibitor
- Trial Type
- Treatment
- Last Update
- 11 months ago
- SparkCures ID
- 1557
- NCT Identifier
- NCT04493164
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.